DMAA PE Ratio & Valuation,Is DMAA Overvalued — Intellectia
DMAA Relative Valuation
DMAA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DMAA is overvalued; if below, it's undervalued.
Historical Valuation
Drugs Made In America Acquisition Corp(DMAA) is now in theFairzone, suggesting that its currentforward PSratio of0.00is consideredFairlycompared with the five-year average of0.00.The fair price ofDrugs Made In America Acquisition Corp(DMAA)is between--to--according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：10.35
Fair
0.00
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Drugs Made In America Acquisition Corp. (DMAA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
Drugs Made In America Acquisition Corp. (DMAA) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.
0.00
PS
Drugs Made In America Acquisition Corp. (DMAA) has a current PS of 0.00. The 5-year average PS is 0.12. The thresholds are as follows: Strongly Undervalued below -2.08, Undervalued between -2.08 and -0.98, Fairly Valued between 1.22 and -0.98, Overvalued between 1.22 and 2.32, and Strongly Overvalued above 2.32. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Drugs Made In America Acquisition Corp. (DMAA) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Drugs Made In America Acquisition Corp. (DMAA) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Drugs Made In America Acquisition Corp (DMAA) has a current Price-to-Book (P/B) ratio of -47.35. Compared to its 3-year average P/B ratio of -275.77 , the current P/B ratio is approximately -82.83% higher. Relative to its 5-year average P/B ratio of -275.77, the current P/B ratio is about -82.83% higher. Drugs Made In America Acquisition Corp (DMAA) has a Forward Free Cash Flow (FCF) yield of approximately -0.15%. Compared to its 3-year average FCF yield of -0.10%, the current FCF yield is approximately 49.06% lower. Relative to its 5-year average FCF yield of -0.10% , the current FCF yield is about 49.06% lower.
-47.35
P/B
Median3y
-275.77
Median5y
-275.77
-0.15
FCF Yield
Median3y
-0.10
Median5y
-0.10
Competitors Valuation Multiple
The average P/S ratio for DMAA's competitors is 0.00, providing a benchmark for relative valuation. Drugs Made In America Acquisition Corp Corp (DMAA) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of DMAA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of DMAA in the past 1 year is driven by Unknown.
Is Drugs Made In America Acquisition Corp (DMAA) currently overvalued or undervalued?
Drugs Made In America Acquisition Corp(DMAA)is now in theFairzone, suggesting that its currentforward PSratio of 0.00is consideredFairlycompared with the five-year average of0.00.The fair price of Drugs Made In America Acquisition Corp(DMAA)is betweentoaccording to relative valuation methord.
What is Drugs Made In America Acquisition Corp (DMAA) fair value?
DMAA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Drugs Made In America Acquisition Corp (DMAA) is between to according to relative valuation methord.
How does DMAA's valuation metrics compare to the industry average?
The average P/S ratio for DMAA's competitors is 0.00, providing a benchmark for relative valuation. Drugs Made In America Acquisition Corp Corp (DMAA) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Drugs Made In America Acquisition Corp (DMAA) as of Dec 15 2025?
As of Dec 15 2025, Drugs Made In America Acquisition Corp (DMAA) has a P/B ratio of -47.35. This indicates that the market values DMAA at -47.35 times its book value.
What is the current FCF Yield for Drugs Made In America Acquisition Corp (DMAA) as of Dec 15 2025?
As of Dec 15 2025, Drugs Made In America Acquisition Corp (DMAA) has a FCF Yield of -0.15%. This means that for every dollar of Drugs Made In America Acquisition Corp’s market capitalization, the company generates -0.15 cents in free cash flow.
What is the current Forward P/E ratio for Drugs Made In America Acquisition Corp (DMAA) as of Dec 15 2025?
As of Dec 15 2025, Drugs Made In America Acquisition Corp (DMAA) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Drugs Made In America Acquisition Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Drugs Made In America Acquisition Corp (DMAA) as of Dec 15 2025?
As of Dec 15 2025, Drugs Made In America Acquisition Corp (DMAA) has a Forward P/S ratio of 0.00. This means the market is valuing DMAA at $0.00 for every dollar of expected revenue over the next 12 months.
